Barclays analyst Carter Gould keeps an Overweight rating on Eli Lilly with a $913 price target after the company presented the tirzepatide SURMOUNT-OSA data. The data “represent a clear win, with compelling consistency across efficacy measures, and no surprises on safety,” the analyst tells investors in a research note. Against high expectations, these data support a “transformative role” in the treatment of sleep apnea, contends the firm. It says the data support the GLP-1 expansion narrative of activity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly files lawsuits to stop sales of counterfeit Mounjaro, Reuters reports
- Eli Lilly (NYSE:LLY) Notches Up on Pursuit of Bogus Mounjaro
- Eli Lilly participates in a conference call with Cantor Fitzgerald
- Insider Trade: Lilly Endowment Sells Eli Lilly Shares Worth $172M
- WHO issues warning on falsified semaglutides
